Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Contributed by: GlobeNewswire

Tags

Financing

More Like This

Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer

Zenas BioPharma Appoints Patricia Allen to its Board of Directors

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

Merus Announces Business Update Conference Call